Citations

Clear

2504 citation(s) found for "Wu, Benjamin".

Secretion Clearance in the Endotracheal Tube Is Influenced by Expiratory Flow and Breath Delivery Profile
McEleney, Pia P, Abdi, Nawal S, Bennett, Mariah, DAWOOD, ABIER M., Stewart, Rylee N, Warsame, Faisa G, LeTourneau, William Michael, Daxon, Benjamin T. , LeTourneau, William M.

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 69 | Issue: 10_suppl | Pages: 4137429-4137429

10.4187/respcare.20244137429 Get It

LGG-10. Diffuse leptomeningeal glioneuronal tumor: a comprehensive clinical and molecular analysis
Mikkelsen, Margit , Li, Xiaoyu, Yu, Kaiwen, High, Anthony A. , Tan, Haiyan, Furtado, Larissa V. , Berry, Julia D., Boué, Daniel R. , Chien, Franklin , Dewan, Michael, Hoffman, Lindsey, Kofler, Julia , Larkin, Trisha , May, Adriana , Noun, Dolly , Schwartz, Jonathan, Sheila, Ivanna, Spiller, Susan, Tanak, Ryuma, Robinson, Giles W, Peng, Junmin, Chiang, Jason, Moreira, Daniel, Li, Xiaoyu, Leelatian, Nalin , Bell, Jessica, Coven, Scott L. , Dewan, Michael Christopher , Foster, Jessica , Hoffman, Lindsey M. , Lazow, Margot , Mobley, Bret C. , Posorske, Benjamin , Schwartz, Jonathan , Qaddoumi, Ibrahim A. , Chiang, Jason

Mayo Clinic

Neuro-Oncology Pediatrics | March 12, 2026 | Volume: 1 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuaf001.193 Get It

Abstract Diffuse leptomeningeal glioneuronal tumors (DLGNT) are rare central nervous system tumors. Our understanding of the clinical course, prognostic factors, and optimal treatment strategies remains limited. Histologic, molecular, and clinical data were collected and analyzed for 25 patients with DLGNT reviewed at St. Jude Children’s Research Hospital. The median age at diagnosis was 6 years (11 months-20 years). Nineteen (72%) patients were male. The disease was localized at diagnosis in 12 (48.0%) patients, with most tumors localized in the spinal cord. BRAF fusion was present in 22 (95.6%) of 23 patients who had material for testing. Of 18 patients who had tissue for DNA methylation profiling, 3 (16.7%) matched to DLGNT MC-1, 3 (16.7%) to DLGNT MC-2, and 12 (66.7%) did not match to a DLGNT subclass. Median follow-up was 63 months. Twenty-four (96.0%) patients received adjuvant therapy after initial diagnosis or at progression. Thirty-five cytotoxic chemotherapy and 24 single-agent targeted therapy regimens were used in 22 and 13 patients, respectively. With targeted therapy, 3 (12%) patients had partial responses. Eleven (44.0%) received radiotherapy. Median progression-free survival (PFS) after a patient’s first chemotherapy, targeted therapy, or radiotherapy regimen was 44 months (1-77), 11 months (4-39), and 16.5 months (9-23), respectively. The 5-year PFS was 18.7%±9.2, while the 5-year overall survival (OS) was 82.4%±9.2. The 5-year OS was lower in patients older than 9 years at diagnosis (60.0%±21.9 vs 91.7%±8.0, p = 0.02). Ki67 >4% was associated with worse PFS (0%±0 vs 24.6%±11.9 at 5 years, p = 0.03). Initial disease dissemination (localized vs. disseminated) and 1q gain status do not influence PFS or OS. PFS for DLGNT remains poor across all treatment modalities, including targeted therapies, despite the high frequency of BRAF fusions. Due to its rarity, establishing optimal therapeutic strategies for DLGNT requires additional treatment and outcome data and prospective multi-institutional trials.
Development of A Screening Tool to Predict Post Intensive Care Syndrome (PICS) in Critically Ill Adults in a Prospective Cohort
Valle, Kathryn T. del , Harris, B. , Clark, Matthew M. , Philbrick, Kemuel L. , Cipriani, Ellie, Cornelius, P., SCHULTE, PHILLIP, Sonsalla, K., Guntupalli, Siva Kamal, Johnson, Andrea, Muir, Kristin, Karnatovskaia, Lioudmila V. , Del Valle, Kathryn T , Harris, Benjamin R E , Cornelius, Patrick , Sonsalla, Kelly, Karnatovskaia, Lioudmila , LeMahieu, Allison , Schulte, Phillip J.

Mayo Clinic

Journal of Intensive Care Medicine | March 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261425642 | PMID 41793150 Get It

Purpose Survivors of critical illness often acquire significant physical, cognitive, and psychological burdens following their intensive care unit (ICU) stay, termed “post-intensive care syndrome” (PICS). Screening for PICS is generally not performed outside of research settings largely due to lack of a simple assessment tool and time constraints. Methods This was a prospective cohort study at a single academic medical center in the USA. We included adults (18 years or older) who spent greater than 48 h in any ICU within the medical center. Following transfer out of the ICU and at 3 months, psychological, cognitive, and physical functioning were assessed using the Hospital Anxiety and Depression Scale, Impact of Event Scale-Revised, Montreal Cognitive Assessment-blind, and Barthel Index. We compared these validated questionnaires to a brief, 15-item PICS screening tool (5 questions/domain) that was developed by our multidisciplinary study team and administered to study participants after ICU discharge to general care. The primary objectives of this study were to assess the ability of validated screening tools administered at ICU discharge to predict PICS at 3 months and develop a novel screening tool for identifying patients at risk of PICS. Major Findings 191 participants completed the initial questionnaire, and 109 (56%) completed the 3-month follow-up. PICS tool scores were compared to 3-month follow-up data from validated questionnaires to evaluate predictive performance. Overall, the screening tool weakly-to-moderately correlated with continuous outcomes of the validated measures at 3-month follow-up. When evaluating sensitivity and specificity for individual domains, the screening tool had an area under curve of >0.7 for all three domains, indicating moderate-to-good sensitivity and specificity. Conclusions We developed a brief PICS screening tool that is feasible to use without prior training that modestly predicted the development of PICS following ICU stay.
Patient‐reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
Kachnic, Lisa A. , Moughan, Jennifer, Hong, Theodore S. , Haddock, Michael G. , Tahir, Naeem, Yoon, Harry H. , Diaz, Dayssy A. , Seaward, Samantha A. , Lominska, C.E. , O’Brien, Paul E. , Chen, Yuhchyau , Salo, J., CHRISTIE, ALFRED D., Aljumaily, R., Gore, Elizabeth , Winter, K., Safran, Howard P., Movsas, Benjamin , Seaward, Samantha A , Lominska, Christopher E , Kachnic, Lisa A , Anderson, Carryn M. , Salo, Jonathan C. , Dorth, Jennifer A. , Aljumaily, Raid, Safran, Howard

Mayo Clinic

Cancer | March 11, 2026 | Volume: 132 | Issue: 6 | Pages: No page available

10.1002/cncr.70345 | PMID 41808581 Get It

Abstract Background NRG/RTOG 1010 evaluated trastuzumab added to trimodality therapy for HER2+ localized esophageal adenocarcinoma (EAC) management. Secondary PRO objectives assessed improvement in the FACT‐Esophageal Cancer Subscale (ECS), version 4, with trastuzumab, and if improved ECS correlated with pathologic complete response (pCR). Methods Patients were randomized to weekly paclitaxel/carboplatin/radiation (chemoradiation, CRT) followed by surgery ± trastuzumab (CRT + Tras). Disease‐free survival (DFS) was the primary end point. The projected PRO sample size of 158 patients, based on an 80% participation rate of the DFS primary endpoint sample size of 197 HER2+ patients, would provide ≥ 89% power to detect ≥25% increase in the proportion of CRT + Tras patients with ECS improvement from baseline to 6–8 weeks post‐CRT; one‐sided α = 0.05, using a χ 2 test. Improvement in ECS and its swallowing index (SI) and eating index (EI) was defined as 5‐, 2‐, and 2‐point increases, respectively, from baseline to 6–8 weeks post‐CRT. Univariate logistic regression was assessed if pCR was associated with improved ECS. Results From 2010 to 2015, 203 HER2+ patients were randomized and 194 were eligible. Of 171 PRO consenting patients, the ECS was completed by 162 (95%) at baseline, 108 (64%) 6–8 weeks, 82 (49%) 1 year, and 55 (33%) at 2 years. The proportion of patients with an improvement in 6–8 weeks ECS was higher on the CRT + Tras arm (46% vs. 38%), although not significantly different ( p = .39). There was no correlation between pCR and ECS scores at 1 year, with 39% and 37% of pCR and non‐pCR patients, respectively, having improved 1‐year ECS scores. Conclusions The addition of trastuzumab to CRT for localized HER2+ EAC did not improve PROs.
Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement
D’Angelo, Christopher R., Godara, Amandeep , Lee, Hans C., Kumar, Shaji, D’Angelo, Christopher R. , Derman, Benjamin A. , Devarakonda, Srinivas , Lee, Hans C. , Robinson, Timothy, Kumar, Shaji , Callander, Natalie S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 9, 2026 | Volume: 24 | Issue: 5 | Pages: No page available

10.6004/jnccn.2025.7105 | PMID 41825121 Get It

Extramedullary presentations of multiple myeloma (MM) involving the central nervous system (CNS) carry a dismal prognosis. Although historically rare, management of extramedullary disease—including CNS manifestations—has become increasingly clinically relevant as advances in systemic therapies have prolonged control of medullary disease. CNS manifestations may occur across a variety of clinical settings and at different time points throughout the disease course. Common symptoms include visual changes, headaches, loss of sensation, confusion, and seizures. MRI identifies leptomeningeal enhancement and/or parenchymal lesions in approximately 90% of cases, and lumbar puncture with cerebrospinal fluid testing for clonal plasma cell populations is confirmatory. Encouragingly, the incorporation of novel therapeutic agents has improved historically poor outcomes in CNS MM. Novel immunotherapeutic approaches using CAR T-cell therapy and bispecific T-cell–engaging antibodies have recently demonstrated significant efficacy in consolidating responses. Multimodality treatment strategies incorporating intrathecal chemotherapy, systemic novel agents, radiation therapy, and immunotherapy hold promise for achieving more durable responses in this devastating manifestation of MM.
Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neuro
Sorenson, Eric J. , Heitzman, Daragh, Lee, Ikjae , Jang, Grace E. , Elman, Lauren , Habib, Ali A. , Wymer, James , Hayat, Ghazala , Fernandes, J Americo M, Floeter, Mary Kay, Ajroud‐Driss, Senda , Gwathmey, Kelly , Ej, Kasarskis, Kisanuki, Yasushi, Lomen-Hoerth, Catherine, Walk, David , Johnston, Wendy S, Diaz, Frank, Maragakis, Nicholas J, Paganoni, Sabrina, Shah, Jaimin, Zinman, Lorne, Heiman-Patterson, Terry, Jawdat, Omar, Fournier, Christina N, Pulley, Michael , Scelsa, Stephen N. , Shoesmith, Christen , Sherman, Alex, Hoover, Benjamin N, Yun, Rebecca, Cheung, Ken, Mitsumoto, Hiroshi , Group, for the PLS NHS Study, Maragakis, Nicholas J. , Sorenson, Eric , Gwathmey, Kelly , Walk, David , Paganoni, Sabrina , Shah, Jaimin , Pulley, Michael T , Simmons, Zachary , Maragakis, Nicholas , Wymer, James, Goutman, Stephen A. , Kasarskis, Edward J. , Lomen‐Hoerth, Catherine , Johnston, Wendy , Diaz, Frank , Oskarsson, Björn , Zinman, Lorne , Heiman‐Patterson, Terry , Fournier, Christina , Simmons, Zachary , Hoover, Benjamin N.

Mayo Clinic

Muscle & Nerve | March 8, 2026 | Volume: 73 | Issue: 6 | Pages: 976-983

10.1002/mus.70192 | PMID 41772409 Get It

ABSTRACT Background Primary lateral sclerosis (PLS) is an ultrarare upper motor neuron syndrome with a prognosis unique from classical ALS. The study of PLS is complicated by its rarity and the difficulty distinguishing PLS from ALS. We present data from a 1‐year prospective follow‐up study on PLS and efforts to distinguish it from ALS. Methods Seventy‐six PLS participants enrolled in this prospective natural history study. EMG studies, blood neurofilament light chain levels (NfLs), and demographic characteristics were obtained at baseline. At 1‐year follow‐up, repeat EMG studies were conducted to determine which participants fulfilled criteria for ALS. Baseline characteristics were then compared to determine features that predict reclassification. Results Seventy participants completed 1‐year follow‐up. Five of the 70 were reclassified to ALS (7.1%). Those reclassified had higher trends in baseline blood NfL levels (91.4 vs. 34.0 pg/mL, p = 0.13) and shorter symptom duration (39 vs. 69 months in the PLS group, p = 0.15). Reclassification was noted in both probable and definite PLS participants. All cases with a symptomatic duration of less than 2 years retained the PLS phenotype (5 of 5). NfL levels over 90 pg/mL predicted reclassification with 94% specificity and 60% sensitivity. No other features predicted reclassification to ALS. Conclusions In our population, reclassification of PLS to ALS occurred at a low frequency at 1 year follow‐up (7.1%). Baseline NfL was the strongest predictor in differentiating UMN dominant ALS from PLS at 1‐year follow‐up. Based on our data, we propose EMG and NfL criteria for enrollment in future PLS trials.
An automated plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease
Levin, Scott , Engel, Brian, Carlson, Corey M., Hinson, Jeremiah, Holland, Mark D. , Figdore, Dan, Tiers, Laurent, Bhatt, Kinal , Schlichtmann, Ben, Hoffmann, Katie, Bae, Ye Eun, Szabo, Miklos, Um, Yoo Hyun , Algeciras-Schimnich, Alicia, Hinson, Jeremiah S. , Figdore, Daniel J. , Lim, Hyun Kook , Schlichtmann, Benjamin W. , Lehmann, Sylvain , Algeciras‐Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | March 8, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71143 | PMID 41789706 Get It

Abstract INTRODUCTION Determining apolipoprotein E ( APOE ) ε4 allele status, a key genetic risk factor for Alzheimer's disease (AD), requires molecular genotyping infrastructure not widely accessible beyond specialized centers. METHODS A fully automated high‐throughput apoE E4 proteotyping immunoassay was evaluated for clinical performance (460 participants across three cohorts) and analytical validity. Concordance with polymerase chain reaction (PCR)‐based genotyping and measures of analytical validity were reported. RESULTS The apoE E4 immunoassay demonstrated 99.6% (95% confidence interval [CI]: 98.4% to 99.9%) concordance with PCR‐based APOE ε4 genotype results across the pooled clinical cohort; 100.0% (95% CI: 97.1% to 100.0%) in those with AD ( N = 127) and 99.4% (95% CI: 97.8% to 99.8%) in those without AD (333). The assay met analytical validity criteria for E4 isoform specificity, interference, precision, and stability. DISCUSSION The apoE E4 immunoassay demonstrated high concordance with PCR‐based genotyping and robust analytical validity, offering an accessible alternative for APOE ε4 zygosity assessment. Highlights A novel high‐throughput plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification was developed and evaluated for clinical performance and analytical validity. The apoE E4 immunoassay demonstrated high concordance (99.6%) with PCR‐based APOE ε4 genotyping across a diverse international cohort, and a robust analytical profile. An apoE E4 immunoassay may offer a more cost‐effective and accessible alternative to DNA genotyping approaches currently used for AD risk evaluation and anti‐amyloid treatment decisions.
The ALT FLOW early feasibility study 3-year results assessing left atrial to coronary sinus shunting in HFpEF
Fioretti, Francesco , Hibbert, B., Labinaz, Marino , Nazer, Babak, Wiley, Mark, Gupta, Bhanu , Sauer, Andrew J, Shah, Hirak , Sorajja, P, Pineda, Andrés M. , Missov, Emil, Aldaia, Lillian , Koulogiannis, Konstantinos , Tedford, R., Gray, William A., Zahr, Firas, Butler, Javed, Hibbert, Benjamin , Hibbert, Benjamin , Sorajja, Paul , Koulogiannis, Kostantinos P , Tedford, Ryan J , Zahr, Firas , Butler, Javed , Eckman, Peter , Simard, Trevor , Nazer, Babak , Wiley, Mark, Sauer, Andrew J , Shah, Hirak, Tedford, Ryan J. , Zahr, Firas , Butler, Javed

Mayo Clinic

ESC Heart Failure | March 6, 2026 | Volume: 13 | Issue: 2 | Pages: No page available

10.1093/eschf/xvag070 | PMID 41814577 Get It

Abstract Introduction Left atrial-to-coronary sinus (LA-to-CS) shunting through the APTURE transcatheter shunt system aims to unload the LA while preserving the interatrial septum. This article aims to examine the 3-year health status, functional capacity, and clinical outcomes of the ALT-FLOW Early Feasibility Study (EFS). Methods Device safety, patency, and echocardiographic parameters, but also symptoms, health status, and exercise capacity were assessed in patients with left ventricular ejection fraction (LVEF) > 40% (n & 95). Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score predicted 3-year all-cause mortality was compared with observed mortality assessed by Kaplan–Meier analysis using adjudicated events. Predicted and observed HF hospitalization (HFH)-free survival rates were also compared. Results At 3 years, the safety profile remained stable with no new safety signals, and all implanted shunts remained patent. 76.3% of patients improved by at least one NYHA class, and mean KCCQ Overall Summary Scores increased by 25 points from baseline (P < .0001). The 6-min walk distance improved by an average of 39 m (P & .002). These benefits were consistent regardless of baseline pulmonary vascular resistance (PVR). Right heart echocardiographic parameters after 3 years were stable, though a reduction in TAPSE was observed, primarily in the high PVR subgroup. The observed 3-year survival was significantly higher than the MAGGIC-predicted survival (84.4% vs 70.2, respectively; P & .009), as well as the HFH-free survival (68.0% vs 24.0%, respectively; P < 0001). Conclusion In patients with HF and LVEF >40%, the APTURE LA-to-CS shunting confirmed an acceptable safety profile with stable right heart parameters and sustained improvements in symptoms, quality of life, and functional capacity at 3 years. Observed survival and HFH were superior to MAGGIC predictions.
An intra-patient contemporaneous comparison of 18 F-piflufolastat and 18 F-flotufolastat urinary radioactivity and local and pelvic region detection rates
Helfand, B.R., Andrews, Jack R. , Kuo, Phillip H. , Gartrell, Benjamin A. , Josephson, David, Saltzstein, Daniel R. , Pathak, Ram , Shore, Neal D., Sykes, James, Penny, Ross, Cohen, Todd, Nordquist, Luke, Purysko, Andrei Saraiva , Shore, Neal D. , Penny, Ross

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 32-32

10.1200/jco.2026.44.7_suppl.32 Get It

32 Background: PET-based radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have become the mainstay of prostate cancer imaging; however, high urinary radioactivity from these primarily renally cleared compounds may obscure tumors in the prostate and peri-ureteric regions. We conducted the first intra-patient comparator study to assess the urinary radioactivity of two 18 F-labelled PSMA-PET radiopharmaceuticals, 18 F-piflufolastat and 18 F-flotufolastat. Methods: This multicenter, prospective, intra-patient comparator study (NCT06604442) enrolled men ≥ 18 years with low PSA (≤ 0.5 ng/mL) biochemical recurrence of prostate cancer ≥ 6 months after radical prostatectomy with undetectable PSA post-surgery, scheduled for a standard-of-care (SoC) 18 F-piflufolastat PET. Patients had a SoC PET/CT after IV 18 F-piflufolastat (target dose 333 MBq), and a second PET/CT 1–10 days later after IV 18 F-flotufolastat (target dose 296 MBq), both scans started approximately 60 min after administration and used the same scanner. The primary endpoint was the difference in urinary bladder radioactivity (mean standardized uptake value [SUV mean ]) between 18 F-piflufolastat PET and 18 F-flotufolastat PET. Secondary endpoints included patient and region-level detection rates (DR) for each radiopharmaceutical. Images were interpreted by two blinded central readers, with a third to resolve disagreements, allowing majority read results. Results: Between Oct 2024 and Jun 2025, 55 patients (mean PSA, 0.28 [range 0.09–0.50] ng/mL) were included in the primary efficacy analysis. Median bladder SUV mean was significantly higher with 18 F-piflufolastat (29.0; interquartile range [IQR], 18.9–40.8) than 18 F-flotufolastat (10.9; IQR, 6.0–18.5) with a median difference of 15.1 (IQR, 8.5–27.0; p<0.001 [Wilcoxon signed-rank test]). The patient-level DR was 27.3% (15/55) for 18 F-piflufolastat and 45.5% (25/55) for 18 F-flotufolastat (majority read). Among the 21 patients with very low PSA levels (≤ 0.2 ng/mL), 38.1% had a positive 18 F-piflufolastat scan compared with 52.4% for 18 F-flotufolastat scans (majority read). Regional and sub-regional DRs are shown in the table. Conclusions: In this intra-patient study, 18 F-flotufolastat showed significantly lower urinary radioactivity, and a higher overall DR than 18 F-piflufolastat indicating it may offer improved image assessment in regions close to the bladder. Clinical trial information: NCT06604442 . Region 18 F-Piflufolastat DR* n (%)N=55 18 F-Flotufolastat DR*n (%)N=55 Prostate bed 6 (10.9) 10 (18.2) Vesicourethral anastomosis 1 (1.8) 4 (7.3) Retrovesical 2 (3.6) 2 (3.6) Remnant seminal vesicles/ lateral surgical margin 2 (3.6) 4 (7.3) Pelvic lymph nodes 8 (14.5) 9 (16.4) Majority read. *≥ 1 PET positive lesion.
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab
Galsky, Matthew D., Drakaki, Alexandra, Basu, Arnab, Bedke, Jens, Loriot, Yohann, Kikuchi, Eiji , Guo, Jun, Garmezy, Benjamin, Sridhar, Srikala S, Klauss, G., Lin, Daisy, Liu, Chelsea, Powles, Thomas, Galsky, Matthew D. , Drakaki, Alexandra , McGregor, Bradley A. , Bedke, Jens , Loriot, Yohann , Guo, Jun , Sridhar, Srikala S , Apolo, Andrea B , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps890 Get It

TPS890 Background: Although first-line (1L) EV + pembrolizumab has improved outcomes for patients with la/mUC, most experience disease progression, highlighting an unmet need for novel therapies. TROP2 is a glycoprotein highly expressed in several epithelial tumors, including UC. Dato-DXd is a TROP2-directed antibody–drug conjugate comprising an anti-TROP2 monoclonal antibody, a tetrapeptide-based cleavable linker, and a topoisomerase I inhibitor payload (DXd), designed to induce selective tumor-cell death and reduce systemic exposure to the payload. Dato-DXd has demonstrated durable efficacy and a manageable safety profile in patients with la/mUC both as monotherapy (TROPION-PanTumor01 [NCT03401385]) and in combination with immunotherapy (TROPION-PanTumor03 [NCT05489211]). We describe a phase 2/3 trial comparing the efficacy and safety of Dato-DXd + platinum CT (carboplatin or cisplatin) vs gemcitabine + platinum CT in participants with la/mUC with disease progression on or after EV + pembrolizumab. Methods: TROPION-Urothelial03 (NCT07129993) is a global, multicenter, randomized, open-label, phase 2/3 trial. In part A (phase 2), ~60 participants will be randomized 1:1 to receive Dato-DXd 4 or 6 mg/kg + platinum CT. In part B (phase 3), ~570 participants will be randomized 1:1 to receive Dato-DXd at the recommended phase 3 dose (determined using part A data) + platinum CT vs gemcitabine + platinum CT. Randomization in part A is stratified by assignment of platinum CT (carboplatin vs cisplatin), and in part B, by assignment of platinum CT, presence vs absence of liver metastasis at screening, and time to progression on 1L EV + pembrolizumab ( < 6 vs ≥6 months). Study treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, death, loss to follow-up, or other reasons per protocol. Radiographic tumor assessments occur every 6 weeks for 54 weeks, then every 12 weeks. The primary endpoint of part A is objective response rate (ORR) by investigator per Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1). The dual primary endpoints of part B are progression-free survival (PFS) by blinded independent central review (BICR) per RECIST 1.1 and overall survival (OS). Secondary endpoints include duration of response by investigator per RECIST 1.1 (part A), and PFS by investigator per RECIST 1.1 and ORR by BICR and investigator per RECIST 1.1 (part B). In part A, ORR will be summarized with 2-sided 95% exact confidence intervals using the Clopper–Pearson method by trial group. In part B, PFS and OS will be compared between trial groups using a log-rank test stratified by randomization stratification factors, with hazard ratios from the stratified Cox regression model. Clinical trial information: NCT07129993 .